AIM ImmunoTech (AIM) Maxim Group’s 2024 Healthcare Virtual Summit summary

Company overview and strategic focus

• Focused on immunology R&D with a lead drug, Ampligen, targeting oncology and antiviral/immunodeficiency applications.

• Current priorities include late-stage pancreatic cancer, advanced recurrent ovarian cancer, and long COVID with chronic fatigue-like symptoms.

• Ampligen is a first-in-class, highly selective TLR3 agonist with a strong safety profile from extensive infusion therapy experience.

• The drug is approved for chronic fatigue syndrome in Argentina and has broad-spectrum potential in solid tumors.

• Many clinical studies are investigator-sponsored, supported by grants and industry partnerships.

Oncology program developments

• Two phase II trials in pancreatic cancer: one in metastatic (with AstraZeneca's durvalumab) and one in locally advanced disease.

• Combination with durvalumab in metastatic pancreatic cancer shows over 60% six-month disease stabilization, compared to 20% in a comparator group.

• Early access program data showed Ampligen alone improved disease stabilization, progression-free survival, and overall survival in both locally advanced and metastatic pancreatic cancer.

• Exploratory biomarkers identified subsets of patients with outstanding survival extension.

• Considering modifying locally advanced trial to include combination therapy based on positive metastatic results.

Mechanism of action and combination therapy potential

• Ampligen stimulates TLR3 in epithelial-rich solid tumors, supporting broad applicability across tumor types.

• Demonstrates synergy with checkpoint inhibitors, potentially overcoming tumor microenvironment resistance.

• May enhance checkpoint blockade therapies by making tumors more visible to the immune system.

• Industry trends now favor combination immunotherapies, aligning with Ampligen’s mechanism.

• Ampligen’s antiviral properties may reduce cancer-related mortality from respiratory viruses.